Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Gland Pharma Limited

Meeting Details

The 48th Annual General Meeting of Gland Pharma Limited was held on Tuesday, August 25, 2026 at 11:00 A.M. IST through Video Conferencing/Other Audio-Visual Means (OAVM). The meeting was conducted virtually in accordance with regulatory requirements.

Proposed Resolutions and Implications

The following five ordinary resolutions were put forth for shareholder approval:

1. Adoption of audited Standalone Financial Statements for FY 2025-26

2. Adoption of audited Consolidated Financial Statements for FY 2025-26

3. Declaration of final dividend on equity shares for FY 2025-26

4. Reappointment of Mr. Wenjie Zhang as Director liable to retire by rotation

5. Reappointment of Ms. Wei Huang as Director liable to retire by rotation

Voting Process and Methods

The Company provided remote e-voting facility through National Securities Depository Limited (NSDL). The remote e-voting window was open from 9:00 AM IST on Saturday, August 22, 2026 until 5:00 PM on Monday, August 24, 2026. Members attending the AGM who had not voted remotely were provided an opportunity to vote through e-voting during the meeting.

Key Financial and Operational Highlights (From Chairman's Address)

  • FY26 Consolidated Revenue: ₹64,307 million
  • FY26 EBITDA: ₹16,295 million with 25% margin (275 bps YoY improvement)
  • FY26 PAT: ₹10,273 million, up 47% YoY with 16% margin
  • Cenexi revenue grew 25% to ₹18,693 million with significant EBITDA improvement
  • Manufacturing capacity: ~1.7 billion units/year across 11 facilities (8 formulation, 3 API)
  • R&D investment: ₹2,230 million with 24 new ANDA filings and 28 product approvals
  • Cumulative ANDA filings: 388 (337 approved, 51 pending approval)
  • Global product registrations: 1,828 across 60+ countries
  • ESG achievements: 5.79% energy conservation, 51.03% water recycling, 21 CSR projects reaching 61,000+ beneficiaries

Attendance Details

Directors Present through VC:

1. Mr. Srinivas Sadu (Executive Chairman) - Hyderabad

2. Ms. Naina Lal Kidwai (Independent Director) - Mumbai

3. Mr. Essaji Goolam Vahanvati (Independent Director) - Mumbai

4. Mr. Udo Johannes Vetter (Independent Director) - Germany

5. Mr. William Robert Keller (Independent Director) - Hongkong

6. Dr. Jia Ai Zhang (Director) - United States

7. Mr. Wenjie Zhang (Director) - Beijing, China

8. Ms. Wei Huang (Director) - Shanghai, China

Management Present through VC (Hyderabad):

1. Mr. Ravi Shekhar Mitra (Chief Financial Officer)

2. Mr. Sampath Kumar Pallerlamudi (Company Secretary & Compliance Officer)

Other Representatives:

1. Mr. Sathya Pramod Koushik (Authorized representative of Statutory Auditors, Deloitte Haskins & Sells)

2. Ms. D Soumya (Scrutinizer and Secretarial Auditor, RVR & Associates)

Member Attendance:

65 members (including speakers) attended the meeting through VC/OAVM.

Scrutinizer's Role and Compliance

Ms. D Soumya of RVR & Associates, Practising Company Secretaries was appointed as Scrutinizer to oversee the voting process. The Chairman authorized the Company Secretary to receive the scrutinizer's report along with the consolidated voting report. The results were to be announced to stock exchanges within two working days and made available on the company website (www.glandpharma.com).

Meeting Duration

The AGM commenced at 11:00 AM and concluded at 12:30 PM IST, including 30 minutes allocated for e-voting during the meeting.